胰島素樣生長因子調控Th17與Treg細胞的平衡
作者:
小柯機器人發布時間:2020/4/20 12:44:26
美國阿拉巴馬大學伯明罕分校Casey T. Weaver研究團隊的一項最新研究顯示,自身免疫反應中胰島素樣生長因子(IGF)是輔助性T細胞17(Th17)調節T細胞平衡的關鍵調控因子。相關論文發表在2020年4月14日出版的《免疫》雜誌上。
研究人員發現在效應T細胞亞群中,Th17和調節性T(Treg)細胞選擇性表達了IGF系統的多個組分。通過IGF受體(IGF1R)傳遞的信號激活了蛋白激酶B、增強了有氧糖酵解;與Treg細胞相比這更有利於Th17細胞的分化,並促進促炎基因的增強表達;蛋白激酶B是哺乳動物雷帕黴素(AKT-mTOR)通路的靶點。
3型先天性淋巴樣細胞(ILC3)而不是ILC1或ILC2對IGF信號有類似的響應。在多發性硬化症/實驗性自身免疫性腦脊髓炎模型(EAE)中,T細胞特異性IGF1R敲出的小鼠未能完全形成該疾病。因此,IGF系統代表了以前未知的通路,通過該通路可以調節3型免疫並控制免疫介導的疾病。
據介紹,Th17和Treg細胞的平衡可維持免疫耐受和宿主的防禦能力。Th17-Treg細胞平衡的破壞與許多免疫介導的疾病有關,其中許多疾病表現出胰島素樣生長因子系統的失調。
附:英文原文
Title: Insulin-Like Growth Factors Are Key Regulators of T Helper 17 Regulatory T Cell Balance in Autoimmunity
Author: Daniel DiToro, Stacey N. Harbour, Jennifer K. Bando, Gloria Benavides, Steven Witte, Vincent A. Laufer, Carson Moseley, Jeffery R. Singer, Blake Frey, Henrietta Turner, Jens Bruning, Victor Darley-Usmar, Min Gao, Cheryl Conover, Robin D. Hatton, Stuart Frank, Marco Colonna, Casey T. Weaver
Issue&Volume: 2020/04/14
Abstract: Appropriate balance of T helper 17 (Th17) and regulatory T (Treg) cells maintainsimmune tolerance and host defense. Disruption of Th17-Treg cell balance is implicatedin a number of immune-mediated diseases, many of which display dysregulation of theinsulin-like growth factor (IGF) system. Here, we show that, among effector T cellsubsets, Th17 and Treg cells selectively expressed multiple components of the IGFsystem. Signaling through IGF receptor (IGF1R) activated the protein kinase B-mammaliantarget of rapamycin (AKT-mTOR) pathway, increased aerobic glycolysis, favored Th17cell differentiation over that of Treg cells, and promoted a heightened pro-inflammatorygene expression signature. Group 3 innate lymphoid cells (ILC3s), but not ILC1s orILC2s, were similarly responsive to IGF signaling. Mice with deficiency of IGF1R targetedto T cells failed to fully develop disease in the experimental autoimmune encephalomyelitis(EAE) model of multiple sclerosis. Thus, the IGF system represents a previously unappreciatedpathway by which type 3 immunity is modulated and immune-mediated pathogenesis controlled.
DOI: 10.1016/j.immuni.2020.03.013
Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30126-6